RecruitingPhase 4NCT05440240

Percutaneous Needle Fasciotomy +/- Corticosteroid Injection for Dupuytren's Contracture

Percutaneous Needle Fasciotomy (PNF) +/- Corticosteroid Injection for Dupuytren's Contracture (DC) Affecting Metacarpophalangeal Joints (MCP) . A Randomized Controlled Trial

Sponsor

Regionshospitalet Silkeborg

Enrollment

400 participants

Start Date

Jan 10, 2023

Study Type

INTERVENTIONAL

Conditions

Neoplasms Musculoskeletal Diseases Neoplasms by Histologic Type Connective Tissue Diseases Neoplasms, Connective and Soft Tissue Neoplasms, Connective Tissue Joint Diseases Dupuytren Contracture Fibroma Neoplasm, Fibrous Tissue Dupuytren's disease contracture

Summary

Comparing percutaneous needle fasciotomy +/- corticosteroid injection for Dupuytren's contracture affecting metacarpophalangeal joints. A clinician-initiated, multicenter, randomized controlled trial.

Eligibility

Min Age: 45 YearsMax Age: 99 Years

Inclusion Criteria4

Sufficient correction of metacarpophalangeal (MCP) joint during the PNF treatment, defined as <20° passive extension deficit (PED), is a prerequisite for inclusion.
Dupuytren contracture (DC) of ≥ 20° PED in MCP joint measured with a goniometer
DC of either II-V finger
Well-defined/palpable cord

Exclusion Criteria12

Legally incapacitated
Previous study inclusion with another finger ray
Isolated proximal interphalangeal (PIP) or distal interphalangeal (DIP) joint contracture, defined as MCP joint contracture < 20° PED regardless of the deficit in the PIP or DIP joint
Previous hand surgery of the affected finger for any reason
Known allergy to the study medication
Anticoagulant therapy (Acetylsalicylic acid is NOT an exclusion criterion)
Pregnant or lactation
Insulin dependent diabetes mellitus
Ongoing systemic infection or local infection at the site of the procedure
Rheumatoid arthritis
Amyloidosis or mucopolysaccharidosis
Unable to communicate, cooperate or participate in follow-up